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Non-alcoholic fatty liver disease is the most common liver disease worldwide. Here, 
we show that the mitochondrial protein mitofusin 2 (Mfn2) protects against liver 
disease. Reduced Mfn2 expression was detected in liver biopsies from patients with 
non-alcoholic steatohepatitis (NASH). Moreover, reduced Mfn2 expression was 
detected in mouse models of steatosis or NASH, and its re-expression in a NASH 
mouse model ameliorated the disease. Liver-specific ablation of Mfn2 in mice 
provoked inflammation, triglyceride accumulation, fibrosis and liver cancer. We 
demonstrate that Mfn2 binds phosphatidylserine (PS) and can specifically extract 
PS into membrane domains, favoring PS transfer to mitochondria, as well as 
mitochondrial phosphatidylethanolamine (PE) synthesis. Consequently, hepatic 
Mfn2 deficiency reduces PS transfer and phospholipid synthesis, leading to 
endoplasmic reticulum (ER) stress and the development of a NASH-like phenotype 
and liver cancer. Thus, ablation of Mfn2 in liver reveals that disruption of ER-
mitochondrial PS transfer is a new mechanism involved in the development of liver 





Non-alcoholic fatty liver disease (NAFLD) is among the most common liver diseases 
worldwide, with increasing prevalence in parallel with the obesity/metabolic syndrome 
epidemic. NAFLD represents a clinical spectrum ranging from simple steatosis and 
non-alcoholic steatohepatitis (NASH) to cirrhosis and hepatocellular carcinoma (HCC)1. 
NASH is accompanied by inflammation, cell death, and fibrosis, and is characterized 
histologically by the presence of ballooning hepatocy es and lobular inflammation with 
or without perisinusoidal fibrosis and steatosis2. Hepatic inflammation is a complex 
process that originates in response to a variety of stress conditions3. In the course of the 
inflammatory process, liver hepatocytes frequently die by programmed cell death. The 
persistent cycle of “necro-inflammation” and hepatocy e regeneration is believed to 
enhance the risk of genetic mutation in hepatocytes, promoting survival and expansion 
of initiated cells. The result is increased cell growth, also referred to as compensatory 
proliferation, which can lead to tumor development4,5. In this context, epidemiological 
and clinical studies have provided convincing evidence that chronic inflammation leads 
to carcinogenesis6-9. 
Several potential factors influencing NASH progression are known to interact10-15, such 
as hepatic endoplasmic reticulum (ER) stress, oxidative stress, mitochondrial 
dysfunction and lipotoxicity. Mitochondrial function is governed by the preservation of 
a normal lipid composition16-19, which is dependent on the capacity of mitochondria to 
synthesize phospholipids, and by the traffic of lipids from the ER to mitochondria20-22. 
Specifically, phosphatidylserine (PS) is primarily synthesized in the ER and is imported 
into mitochondria by transient membrane contact between mitochondria-associated ER 
membranes (MAMs) and the mitochondrial outer membrane23. In mitochondria, PS is 
converted into phosphatidylethanolamine (PE), which is then  imported into the ER for 
conversion to phosphatidylcholine (PC)16,21,24,25. Accordingly, MAMs are key sites for 
synthesis and traffic of phospholipids17,25.  
Mitofusin 2 (Mfn2) is a mitochondrial membrane protein with a role connecting ER 
membranes to mitochondria26-28, and its depletion causes ER stress29-31. Mfn2 plays a 
relevant role in the maintenance of mitochondrial metabolism, insulin signaling and 
energy homeostasis30-33. Cancer cells of different origin show a low expression of Mfn2 
34-37. In addition, Mfn2 levels are significantly downregulated in HCC tissue compared 
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with corresponding adjacent normal tissue, and there is a negative correlation between 
Mfn2 levels and the prognosis of cancer38-40. Mfn2 overexpression in hepatocellular 
carcinoma or colorectal cancer cells  reduces cell pro iferation and induces spontaneous 
apoptosis35,37. However, it is unknown whether Mfn2 downregulation is a cause or a 
consequence of cancer, and in addition, there are no data linking Mfn2 to NALFD 
progression.  
Here we show that hepatic Mfn2 is downregulated both in patients with NASH, and in 
subjects borderline for NASH. Further, mouse models of hepatic lipid accumulation or 
NASH present lower levels of Mfn2 in liver, and the re-expression of Mfn2 in liver 
ameliorates the NASH phenotype. We also demonstrate hat hepatic Mfn2 ablation 
causes a NASH-like phenotype that progresses to liver cancer with age. We show that 
Mfn2 binds to and participates in the transfer of PS. Accordingly, hepatic Mfn2 
deficiency causes a reduced transfer of PS from ER to mitochondria, which leads to 
reduced PS synthesis and ER stress, in turn causing inflammation, fibrosis and liver 
cancer. Overall, our data strongly suggest that Mfn2 constitutes a new target for the 




Human liver samples of non-alcoholic steatohepatitis present low levels of Mfn2  
To investigate whether Mfn2 is dysregulated in NASH, we compared its expression in 
liver biopsies from patients with steatosis or NASH. Clinical, anthropometric, and 
biochemical data of this cohort have been reported pr viously41. Results showed that 
protein levels of Mfn2 were significantly lower in liver from patients with NASH than 
in subjects with simple steatosis (Figure 1A). We also analyzed human liver biopsies 
from a second cohort of subjects without NASH (NAS index <3) and close to borderline 
NASH (NAS index ≥5). NAS scoring was performed according Takeda et al.,42. 
Clinical characteristics of these patients are shown in Supplementary Table 1. Both 
Mfn2 mRNA and protein levels were significantly decr ased in patients with borderline 
NASH (Figures S1A, S1B and S1C). By contrast, expression of the Mfn2 homologue 
Mfn1 was unaltered in this group (Figure S1D). Overall, these data show that Mfn2 is 
down-regulated in human liver during progression from steatosis to NASH.  
 
Mouse models of non-alcoholic liver disease have low hepatic levels of Mfn2 
To document the possible involvement of Mfn2 in NALFD, we studied its expression in 
C57BL6/J mice with steatosis induced by high-fat diet (HFD) over three weeks, a time 
sufficient to trigger hepatic steatosis43. Mfn2 protein expression in liver was significanly 
lower in the HFD group than in the control group (Figures 1B, and S1E). Because mice 
on HFD show fatty liver and obesity but not fibrosis44, we utilized a well-established 
mouse model of NASH consisting of a methionine/choline-deficient diet combined with 
45% HFD and supplemented with 0.1% L-methionine in drinking water, to avoid 
weight loss44 (hereafter termed MCD). C57BL6/J mice on MCD diet for 3 weeks 
showed substantial fat accumulation and liver fibrosis (detected by H&E and Sirius Red 
staining, respectively) (Figure 1C). Further, liver triglyceride levels and mRNA levels 
of inflammatory markers and the fibrotic marker TGFβ were significantly higher in 
mice on MCD diet than on control diet (Figures 1D, S1F and S1G). Under these 
conditions Mfn2 levels were diminished (Figures 1E, and S1H), and this decrease was 
greater in mice on MCD diet than on HFD (Figure 1B and 1E). Consistent with the data 
in human biopsies, Mfn1 protein levels were unaltered in mice on MCD diet (Figure 
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S1I). These results are consistent with a specific progressive repression of Mfn2 in 
mouse liver disease. 
 
Mfn2 ablation causes chronic hepatic inflammation and bnormal lipid metabolism 
To substantiate the role of Mfn2 in liver as a trigger of the NASH-like phenotype, we 
analyzed liver-specific Mfn2 knockout mice (L-KO) generated in our laboratory31. 
Under normal chow diet, 8 week-old L-KO mice showed a significant increase in the 
abundance of hepatic and plasma pro-inflammatory cytokines (Figures 1F, S2A and 
S2B), expression of hepatic pro-inflammatory genes (Figure S2C) and a modest but 
significant accumulation of triglycerides (Figure 1G). This occurred in the absence of 
changes in body weight, food intake or circulating lipids (Figures S2D–H). Further 
analysis of lipid metabolism in hepatocytes isolated from L-KO and control mice 
revealed that the esterification of oleate into diacylglycerol and triacylglycerol was 
enhanced in the former, but their incorporation into phospholipids was decreased 
(Figure 1H). Under these conditions, oleate β-oxidation was decreased in Mfn2-
deficient hepatocytes (Figure S2I). Further, the expr ssion of de novo lipogenesis and 
esterification genes was modestly elevated in liver from L-KO mice (Figures S2J). In 
sum, L-KO mice show a pattern typical of disturbances in hepatic lipid metabolism. 
 
Mfn2 ablation causes apoptosis, increased cell growth, fibrosis and liver cancer 
It is known that chronic hepatic inflammation is associated with enhanced apoptosis, 
leading to compensatory cell proliferation and fibrosis, which are known risk factors for 
liver cancer45,46. Given the chronic inflammation detected in L-KO mice, we analyzed 
the development of these processes to determine whether Mfn2 deficiency leads to liver 
cancer progression. Under normal conditions, apoptosis was higher in liver from L-KO 
mice than from controls, as demonstrated by increased levels of cleaved PARP-1 and 
cleaved caspase-3 (Figures S3A and S3B), and was accompanied by a higher number of 
Ki67-positive cells (Figure S3C), indicating enhanced proliferation. Furthermore,  the 
expression of genes encoding fibrotic markers was also elevated in L-KO livers (Figure 
1J), and Sirius red staining and transmission electron microscopy revealed a marked 
accumulation of extracellular collagen in livers at 27 weeks of age (Figure 1I).  
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We next explored whether hepatic Mfn2 deficiency promotes liver cancer as a 
consequence of the natural progression of liver disease. Accordingly, L-KO and control 
mice on normal diet were examined for liver tumors at twenty-four months of age. 
Analysis showed that the number of tumors was significantly higher in L-KO mice than 
in control mice, and tumor volume was also greater (Figures 1K and S3D). We next 
sought to validate these results by investigating whether L-KO mice showed a 
differential predisposition to the liver-specific car inogen diethylnitrosamine (DEN). 
Treatment of mice with DEN triggers a well-known cas de of events in liver that 
include DNA damage and apoptosis of centrilobular hepatocytes, production of 
proinflammatory cytokines and compensatory proliferation47. As a first approach, we 
induced liver DNA damage with a single high-dose intraperitoneal injection of DEN (50 
mg/kg) to assess the acute liver response. Immunohistological examination of livers 48 
h after DEN injection revealed a stronger DNA damage response in centrilobular 
regions in L-KO mice than in controls, and this accompanied by greater levels of 
compensatory proliferation (Figures S3E, S3F, and S3G). We next treated control and 
L-KO mice with a single lower dose of DEN (5 mg/kg), followed by continued 
exposure to HFD. After seven months L-KO mice subjected to DEN-HFD treatment 
showed a larger number of tumors and greater tumor size compared to control treated 
mice (Figure S3H). Thus, our data indicate that hepatic Mfn2 ablation leads to 
apoptosis, increased cell proliferation, fibrosis, and a greater susceptibility to develop 
liver cancer.  
 
Mfn2 re-expression restores normal liver metabolism in L-KO mice 
To assess whether the alterations detected in Mfn2-deficient livers were attributable to 
Mfn2 loss-of-function or to compensatory mechanisms, we re-expressed Mfn2 in L-KO 
mice by intravenous administration of adenoviruses encoding either Mfn2 or LacZ 
(AdC, used as a control). Upon Mfn2 re-expression (Figure S4A) hepatic and plasma 
cytokines returned to control levels (Figures S4B–D) and the expression of fibrosis 
genes and pro-inflammatory genes were markedly down-regulated (Figure S4E and 
S4G). Moreover, triacylglycerol levels were normalized (Figure S4F), and oleate β-
oxidation was enhanced (Figure S4H).  
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We have previously reported that under normal chow diet, 8-week-old L-KO mice 
present an elevated unfolded protein response (UPR)31. Thus, we surveyed the impact of 
Mfn2 re-expression on ER stress markers. Results showed that Mfn2 re-expression 
normalized  the different UPR parameters (Figure S4I). These data strongly suggest that 
Mfn2 is directly responsible for the liver abnormalities found in L-KO mice. 
 
Normalization of ER stress triggered by Mfn2 deficiency ameliorates inflammation and 
fibrosis but not the impaired lipid metabolism 
The up-regulation of UPR proteins, such as CHOP, is sufficient to promote liver 
apoptosis, inflammation, compensatory proliferation, fibrosis and liver cancer48. To 
begin to elucidate the mechanisms by which Mfn2 deficiency triggers the development 
of cancer, we examined the contribution of ER stres to these processes in the L-KO 
model. We blocked ER stress by overexpressing a critical regulator of UPR signaling, 
BIP (GRP-78). Because hepatic BIP gain-of-function in control mice has been shown to 
cause hypoglycemia and sudden death, even upon administration of very low levels of 
adenovirus, in models that do not present UPR activtion (data not shown and previous 
reports49,50), we expressed BIP by adenoviral intravenous injection only in L-KO mice, 
which show chronic ER stress.    
Acute BIP overexpression decreased UPR signaling in L-KO mice (Figure 2A, and 
S5A). Moreover, liver and plasma circulating pro-inflammatory cytokines were 
normalized by BIP (Figure 2B, and 2C), and the exprssion of genes encoding pro-
inflammatory or fibrotic factors was also markedly lower than that seen in equivalent 
controls (Figure 2D and S5B). Similarly, apoptosis and cell proliferation were decreased 
in L-KO mice expressing BIP (Figure S5C–D). In the context of mitochondrial 
metabolism, BIP expression enhanced oleate oxidation (Figure S5E) and reduced ROS 
production measured as hydrogen peroxide (Figure S5F), thereby recovering 
mitochondrial function, which is in keeping with our previous data29. Intriguingly, BIP 
overexpression failed to restore hepatic triglycerid  levels (Figure 2E) or the 
incorporation of oleate into lipids (Figure 2F). These data indicate that the hepatic 
mitochondrial dysfunction, inflammation, fibrosis, apoptosis and increased proliferation 




Mfn2 plays a crucial role in hepatic phospholipid metabolism 
It has been reported that an aberrant phospholipid composition of the ER membrane is a 
potent activator of the UPR51-53. Accordingly, we studied the total hepatic phospholipid 
content in L-KO mice in an attempt to identify mechanisms linking Mfn2 deficiency 
and UPR. Results from lipidomics analysis showed that L-KO mice had a decreased 
abundance of total hepatic PE and PC species (Figure 3A; statistical significance of the 
data is shown in Supplementary Table 2). Consistent with these data, the lipidomics 
profile of hepatic MAMs and mitochondrial fractions from L-KO and control mice was 
different (Figures S6A, and S6D), with a decrease in the abundance of PE and PC 
species in the former (Figures S6B, S6C, S6E, and SEF; Supplementary Table 3). 
Because Mfn2 and some proteins of hepatic phospholipid synthesis are localized in 
mitochondria-ER contact sites (schematic shown in Figure 3B)26,29,54,55, we monitored 
the incorporation of radiolabeled L-serine (L-Ser) into PS, PE, and PC in hepatic MAM 
fractions from control and L-KO mice. We found that this incorporation was 
significantly decreased in MAM fractions from L-KO mice (Figure 3C–E).  
We next questioned whether ER stress plays a role in the defects detected in 
phospholipid synthesis by analyzing BIP-expressing L-KO mice. BIP expression failed 
to improve the incorporation of L-Ser into PS, PE or PC (Figure 3F); however, re-
expression of Mfn2 completely rescued L-Ser incorporati n into phospholipids (Figure 
3G). Overall, our data indicate that hepatic Mfn2 depletion alters phospholipid synthesis 
and that these effects are not a consequence of ER stress. 
Phospholipid metabolism in mammalian cells depends on the activity of many enzymes 
including phosphatidylserine synthase 1 (PSS1), phos atidylserine synthase 2 (PSS2), 
and PE N-methyltransferase (PEMT), which are localized in MAMs and the ER; and PS 
decarboxylase (PISD), which is found in mitochondria20,21. We therefore analyzed 
whether loss of Mfn2 altered the expression of these proteins. Analysis by western 
blotting showed that the hepatic expression of PSS1 and PSS2 proteins was 
significantly lower in L-KO mice than in control mice (Figure 3H), whereas no changes 
were observed for PEMT (Figure S6G) or PISD (data not shown).  
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We next assessed the protein composition in MAMs by examining the abundance of 
MAM-enriched proteins in liver upon subcellular fractionation (Figure 3I and S6H). 
Western blotting of hepatic MAM fractions revealed a 50% reduction in PSS1 
expression in L-KO mice (Figure 3I), whereas no changes were found for PSS2 whose 
expression was barely detectable (Figure 3I, and Figure S6I). Moreover, levels of 
PACS-2, Sig1R, and calnexin were elevated in MAMs from L-KO mice (Figures 3I, 
S6H, and S6I), which resembles the alterations in MAM composition in models of 
insulin resistance and aberrant lipid metabolism52,56. Thus, our results suggest that Mfn2 
regulates phospholipid biosynthesis through PSS1 and PSS2 protein levels.   
 
Alterations of lipid metabolism in L-KO mice are independent of the distance between 
ER and mitochondria 
Given the role of Mfn2 in tethering ER to mitochondria 26-28, we explored whether the 
distance between mitochondria and ER might regulate phospholipid synthesis in Mfn2-
ablated conditions. To do this, we used a recombinant adenovirus construct encoding a 
synthetic linker (RFP-linker) that increases the number ER-mitochondria contact sites, 
thus forcing ER-mitochondria interactions in L-KO mice (Figure S7A). Western blot 
analysis of RFP expression confirmed the expression of the linker (Figure S7A). L-KO 
mice expressing this linker showed a normalization of L-Ser incorporation into PS 
(Figure S7B); however, it failed to correct the synthesis of PE or PC, hepatic 
triacylglyceride levels, ER stress or PSS1 expression (Figures S7B–S7F). Under these 
conditions, PSS2 abundance was actually enhanced in L-KO mice (Figure S7F), which 
may explain the normalization of PS synthesis (Figure S7B). These results indicate that 
altered ER-mitochondria contact does not explain the lower synthesis of PE and PC in 
MAMs of Mfn2-deficient livers. 
 
Down-regulation of hepatic PSS1/2 phenocopies Mfn2 ablation 
In light of the above findings, we hypothesized that a decrease in phospholipid synthesis 
in MAMs causes hepatic triglyceride accumulation and ER stress in liver. To test this, 
we induced downregulation of either PSS1 or PSS2 in wild-type mice. Silencing of 
PSS1 by intravenous injection of a specific shRNA adenovirus caused the upregulation 
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of hepatic PSS2 and vice versa (Figure S8A,B), observations that are in agreement with 
previous data57-61. On the basis of these findings, which point to a strong adaptation 
process, we silenced both PSS1 and PSS2 in wild-type mice using two specific shRNA 
adenoviruses, which decreased the hepatic expression of both proteins by ~90% (Figure 
4A and S8C). Analysis of hepatic MAM fractions showed a significant decrease of 
PSS1 in PSS1/2 knockdown (hereafter termed KD) mice (Figure 4B). This resulted in a 
decrease in the incorporation of L-Ser into PS and PE (Figure 4C) and an increase in 
hepatic triacylglycerol and oleate incorporation into lipids (Figure 4D and S8D). KD 
mice also showed ER stress (Figure 4E and S8E), and a higher expression of the fibrosis 
gene α-SMA and pro-inflammatory genes in liver (Figure 4F and S8F). In keeping with 
these observations, levels of hepatic pro-inflammatory cytokines were elevated in KD 
livers (Figure S8G); however, mitochondrial function (oleate oxidation or liver 
hydrogen peroxide production) was unaltered (Figure S8H and S8I).  
 
Analysis of MAM protein composition revealed alterations in response to hepatic 
PSS1/2 silencing, with a significant decrease of Mfn2 expression in KD mice (Figure 
4G). Also, PACS-2, Sig1R, and calnexin proteins were more abundant in MAMs from 
KD mice (Figures S8J–S8L), thus mirroring the alterions in MAM composition in 
Mfn2 L-KO mice. Overall, these results indicate that hepatic PSS1/2 deficiency 
recapitulates many of the hepatic alterations caused by Mfn2 ablation.  
We next attempted to counter the liver alterations in L-KO mice by overexpressing 
PSS1 (Figure 4H). PSS1 overexpression led to an upreg lation of Ptdss2 mRNA in L-
KO mice (Figure 4I). As expected, we also found an increase in the synthesis of PS 
(Figure 4J), and surprisingly the normalization of liver triglycerides (Figure 4K). By 
contrast, PSS1 overexpression failed to rescue the synthesis of PE or PC (Figure 4J), or 
ameliorate the UPR (Figure 4L and S8M). Taken together, our data show that Mfn2 
depletion causes a fundamental defect that prevents the ynthesis of PE from PS.  
 
Mfn2 is a PS-binding protein and generates PS-rich domains in membranes  
A key process in the synthesis of phospholipids in MAMs is the transfer of PS and PE 
between the ER and mitochondria20,22,25. To determine whether Mfn2 was involved in 
PS transfer, we first investigated whether it binds phospholipids by assaying binding of 
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immunoprecipitated Mfn2 to lipid strips. Mfn2 was specifically immunoprecipitated 
under denaturing immunoprecipitation conditions with a polyclonal antibody. Mfn2 
specifically bound phosphatidate (PA) and PS but not ph sphatidylinositol (PI), PE or 
PC (Figure 5A). To validate this binding to phospholipids and to exclude the possibility 
that it was due to transmembrane domains, we constructed a truncated version of Mfn2 
lacking the transmembrane domains and the C-terminal cytosolic portion (1–613), but 
preserving some metabolic characteristics of the full-length protein62.  L-KO mice were 
tail vein injected with an adenoviral vector permitting the hepatic expression of this 
short form containing a 6×His tag at the N-terminus. We then purified the recombinant 
Mfn2 protein under denaturing conditions by affinity chromatography. Results showed 
that Mfn2 (1–613) could also specifically bind PS and PA (Figures 5B). To determine 
its potential in vivo role on phospholipid synthesis, we analyzed the eff cts on 
phospholipid synthesis by monitoring the incorporati n of labeled L-Ser in the same L-
KO mice. Data revealed that Mfn2 (1–613) enhanced the incorporation of L-Ser into 
PS, PE and PC (Figure 5C).  
 
For in vitro analysis, we expressed Mfn2 (1–613) in E. coli and purified the protein by 
affinity chromatography that, after elution, represented >60% of the Comassie blue-
stained proteins in gel electrophoresis (Figure 5D). Eluted Mfn2 (1–613) was also 
identified by mass spectrometry and contaminants were detected at very low levels 
(Supplementary Table 4). When we analyzed the capacity of the recombinant protein to 
bind phospholipids, we observed specific binding to PS and to PA in lipid strip assays 
(Figures 5E), consistent with the results in the liv r. To exclude false positive binding 
due to phospholipid positioning in the strip, we performed liposome flotation assays, 
which confirmed that Mfn2 (1–613) mainly bound PS conjugated to a fluorophore 
(NBD) and also natural PS (Figures 5F and S9A) in liposomes. Overall, these data 
indicate that Mfn2 shows a capacity to selectively bind PS with minimal binding to 
natural PA and PI.  
We next determined whether Mfn2 participates in the transfer of PS between 
membranes. We first evaluated its capacity to extract PS from liposomes, which may 
account for the alterations in the synthesis of PE in L-KO liver, even upon PSS1 
overexpression. Phospholipid extraction was performed as described by Kawano et al63.  
Purified Mfn2 (1–613) was incubated with liposomes containing labeled phospholipids 
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(NBD-PS or NBD-PE) and the mixture was then separated by gradient centrifugation 
(Figure 5G). Subsequently, we analyzed the liposome-containing fraction and the non-
liposome-containing fraction. Analysis of the distribution of NBD fluorescence in the 
presence of Mfn2 revealed that the fluorescence of NBD-PS decreased in the liposome 
fraction and increased in the non-liposome fraction (Figure 5H), whereas the 
distribution of NBD-PE fluorescence was unchanged both in the presence or absence of 
Mfn2 (Figure S9B).   
In accord with these data, confocal microscopy revealed that Mfn2 (1–613) induced the 
formation of rigid domains containing exclusively NBD-PS (green color) from 
liposomes containing both NBD-PS (green) and Rhodamine-PE (red) (Figure 5I). Lipid 
domains were not generated when Mfn2 (1–613) was exposed to liposomes containing 
NBD-PC and Rhodamine-PE (Figure S9C). Given the unexpected capacity of Mfn2 (1–
613) to generate PS-rich domains in membranes, we evaluated whether this capacity 
showed time-dependence and if it occurred with different types of liposomes. Using a 
well-established fluorescence resonance energy transfer-based membrane assay64,65, we 
incubated control and Mfn2 (1–613) proteins with a mix of donor liposomes (containing 
NBD-phospholipids and Rhodamine-PE) and acceptor lip somes (non-fluorescent). The 
presence of Mfn2 (1–613) induced the release of NBD fluorescence in a time-dependent 
manner in liposomes containing NBD-PS but not NBD-PE (Figures 5J and S9D). 
Similar results were obtained using liposomes containing fluorescent TopFluor 
(TopFluor-PS or TopFluor-PE) derivatives of phospholipids, which are smaller in size 
than NBD-phospholipids (Figures S9E, and S9F). Our results support the view that 
Mfn2 binds PS and has the capacity to isolate it from membranes and to form rigid 
domains enriched in PS. These findings are consistet with a role for Mfn2 in 
exchanging lipids from different membranes or remodeling them in membranes, which 
may be due to lipid rearrangement. 
 
PS-dependent remodeling activity of Mfn2 requires an intact N-terminal region 
To address the specificity of Mfn2 functions, we tested whether Mfn1 has the same 
activities. To evaluate similar protein fragments in Mfn1 and in Mfn2, we expressed a 
recombinant truncated version of Mfn1 (1–592) in E. coli, which was purified under 
identical conditions as for Mfn2 (1–613) (Figure 6A). We first determined whether 
15 
 
Mfn1 (1–592) had phospholipid-binding activity. Liposome flotation assays revealed 
that, in contrast to Mfn2 (1–613), Mfn1 bound PC, PE, and PS phospholipids to a 
similar extent (Figure 6B). In a second analysis, lipid extraction assays revealed that 
Mfn1(1–592) failed to extract NBD-PS from liposomes (Figure 6C), but it did extract 
NBD-PE (Figure 6D), pointing to distinct functions for Mfn1 and Mfn2.   
To better understand the basis for the differential capacity of Mfn1 and Mfn2 to bind 
and extract phospholipids, we examined the amino acid sequences of the two proteins 
(Figure 6E). Alignment analysis revealed that the N-terminal (20 aa residues) sequence 
of Mfn2 was absent in Mfn1. We then expressed and purified a mutant form of Mfn2 
lacking this fragment (referred to as Mfn2 21–613) in E.coli (Figure 6F) and used it in 
liposome flotation assays. Results showed that Mfn2 (21–613) bound to PS, PE, PC 
(Figure 6G). Notably, lipid extraction assays revealed that purified Mfn2 (21–613) 
extracted both NBD-PS and NBD-PE from liposomes (Figure 6H and 6I). Thus, the 
Mfn2 (21–613) mutant combines the properties of both Mfn1 and Mfn2, suggesting that 
the N-terminal fragment is key to confer selectivity to extract PS.  
 
Re-expression of Mfn2 in mice on MCD diet alleviates liver disease  
After establishing the unique action of Mfn2 on phospholipid partition and metabolism, 
we next examined the consequences in liver under conditi ns of reduced Mfn2 
expression during NASH. Specifically, we assessed whether the reduced Mfn2 levels in 
mice on MCD diet was linked to impaired PS transfer and whether it was key to the 
pathological alterations. We also investigated the possible role of ER stress in this 
scenario. Mice were placed on MCD or chow diet for two weeks and were then 
intravenously injected with a control adenovirus or with adenoviruses encoding Mfn2 or 
BIP, and livers were studied one week later. Hepatic Mfn2 expression was normalized 
in MCD mice upon injection of Mfn2 adenoviruses (Figures S10A, and S10C), whereas 
BIP failed to recover Mfn2 levels (Figures S10B and S10C). Compared with the control 
diet, the MCD diet induced an enhanced incorporation of radiolabeled L-Ser into PS, 
and a low synthesis of PE and PC in hepatic MAMs (Figure 7A). Mfn2 re-expression 
normalized the incorporation of L-Ser into PE and PC, whereas BIP did not ameliorate  
as Mfn2 the low levels of phospholipid synthesis (Figure 7A). 
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Analysis of fibrosis in liver sections of MCD diet-fed mice showed that Mfn2-re-
expressing mice had less Sirius red staining than mice treated with control adenovirus 
(Figure 7B), whereas the expression of BIP only partially diminished fibrosis (Figure 
7B). Similarly, triglyceride accumulation in liver was decreased upon Mfn2 re-
expression as assessed by H&E staining (Figure 7B), and by quantification of 
triglycerides (Figure 7C). By contrast, BIP expression failed to normalize hepatic 
triglycerides in MCD diet-fed mice (Figure 7B, and 7C). As expected, the expression of 
inflammatory and fibrosis markers was markedly decreased by Mfn2 re-expression, but 
not by BIP overexpression (Figures 7D). Finally, both BIP and Mfn2 treatments 
normalized all UPR markers upregulated in MCD mice (Figure S10D). 
Overall, our data strongly suggest that Mfn2 repression plays a key role in the 
development of steatosis, inflammation and fibrosis in a mouse model of NASH. 
Moreover, we have identified a defect in phospholipid synthesis in MCD diet-fed mice, 
which it is crucial for the development of the pathology. Our data are consistent with a 
major role of Mfn2 in the normalization of PS transfer from ER to mitochondria, which 








We report that Mfn2 plays a key role in liver homeostasis by controlling both PS 
transfer from ER to mitochondria and the UPR. Accordingly, hepatic ablation of Mfn2 
results in unbalanced phospholipid metabolism, leading to ER stress and triggering liver 
inflammation and fibrosis, which takes place early in the life of these mice and occurs 
even on a normal diet and in the absence of obesity. In addition, mice with liver-specific 
knockout of Mfn2 have enhanced susceptibility to liver cancer with age or in response 
to carcinogenic agents. Supporting the clinical relevance of these findings, we show that 
hepatic Mfn2 expression is lower in patients with NASH than in those with steatosis. 
Mfn2 expression is also repressed in mouse models of steatosis and NASH, and its re-
expression diminishes NASH-like liver pathologies. Taken together, our data indicate 
that hepatic Mfn2 is a key protein to maintain healthy iver function and its repression is 
involved in the development of liver disease.  
 
We show that the UPR caused by Mfn2 deficiency plays  key role in the development 
of hepatic inflammation, apoptosis, compensatory proliferation and fibrosis, which in 
turn contributes to the development of liver cancer48. Thus, normalization of UPR 
response by BIP gain-of-function restores inflammation to control levels and reduces 
apoptosis, hyper-proliferation and fibrosis, which would prevent the development of 
cancer. These results are consistent with our previous observations that deficient hepatic 
insulin signaling is normalized in Mfn2 knockout mice treated with 
tauroursodeoxycholic acid31. Indeed, chronic ER stress plays a key role in the 
pathophysiology associated with Mfn2 deficiency, and ppears to be responsible for the 
alterations in mitochondrial metabolism that have been detected in Mfn2-deficient 
cells29. The fact that inflammation, fibrosis and insulin resistance are modulated by ER 
stress may explain the relationship reported between st atosis, insulin resistance, and 
NASH48,52,66-68. 
 
We found that Mfn2 re-expression normalizes liver function in a mouse model of 
NASH, whereas BIP expression only partially counters steatosis, inflammation and 
fibrosis. These findings indicate that whereas Mfn2 likely plays a key role in the 
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development of liver disease in murine NASH, the UPR is a secondary contributing 
factor.  
 
Our data also reveal that Mfn2 deficiency markedly impairs phospholipid metabolism 
and this lies upstream of the UPR. Thus, BIP-induce amelioration of UPR failed to 
normalize lipid metabolism. The changes in phospholipid metabolism associated with 
Mfn2 deficiency were characterized by lower rates of synthesis of PS, PE and PC, 
reduced expression of phosphatidylserine synthases PSS1 and PSS2, and reduced 
abundance of PSS1 in MAM fractions. We also found that a reduction in hepatic 
phospholipid metabolism explains the enhanced accumulation of triglycerides, the UPR 
and inflammation. While the re-expression of PSS1 was not sufficient to mitigate the 
defective synthesis of PE and PC in Mfn2-depleted livers, it significantly reduced 
hepatic triglycerides, revealing a close regulation of phospholipid and triglyceride 
synthesis in MAMs. Expression of both full-length and truncated Mfn2, lacking the 
transmembrane domains, improved phospholipid metabolism in Mfn2-deficient livers. 
Thus, our results indicate that loss of hepatic Mfn2 expression changes phospholipid 
metabolism by altering two different steps: 1) reducing the transfer of PS from the ER 
to mitochondria, and 2) inhibiting PS synthesis as a consequence of a compensatory 
reduced expression of PPS1 and PSS2. 
 
Importantly, we describe a new molecular function of Mfn2 in the maintenance of 
hepatic phospholipid metabolism. Mfn2 has the capacity to bind PS in vitro, and to 
cause partitions of PS into rigid membrane domains. These activities are specific for PS 
and are not found with other phospholipids such as PE or PC.  Indeed, these data may 
be key to understand the molecular basis for the multiple cellular effects of 
Mfn226,31,32,69. In addition, our observations provide molecular insights into the step  
involved in the transfer of PS from ER to mitochondria. We propose that Mfn2 
participates in the generation of PS-enriched domains t the ER-mitochondria contact 
sites and they favor the activity of potential PS transport proteins such as the oxysterol-
binding protein (OSBP)-related proteins ORPs (ORP5/ORP8) or VAT-1. ORP5/8 binds 
PS in vitro70 and mediates PI4P/PS counter transport between the ER and the plasma 
membrane71.  These proteins have also been identified in MAMs72 and therefore may 




The observation of a link between Mfn2 and phospholi ids is highly relevant because of 
their influence on membrane-dependent cellular functions, antioxidant, anti-
inflammatory, anti-fibrotic properties, and cellular signaling73,74. Thus, obesity has been 
reported to increase the hepatic PC/PE ratio which inhibits SERCA activity75. In 
addition, genetic inhibition of PEMT, which catalyzes the conversion of PE to PC, 
relieves ER stress and improves systemic glucose homeostasis in obesity75,76. Mfn2 
levels are increased in MAMs in obese mice56 under conditions in which enhanced PC 
production has been reported75. Furthermore, low levels of phospholipids in bile due to 
the disruption of membrane transporters are linked to liver disease77,78. Another 
important feature of our work is the observation that epatic Mfn2 ablation provokes 
MAM remodeling similar to that detected in HFD or genetic obesity. This is also 
relevant because remodeling of MAM interactions in liver in obesity has been shown to 
result in undesirable side effects such as triacylglycerol accumulation and insulin 
resistance56. Specifically, hepatic MAM shows an enhanced abundance of protein 
markers such as PACS2, IP3R1, and IP3R2 during obesity56, which is consistent with 
the pattern of changes detected in Mfn2-deficient livers. Accordingly, we propose that 
alterations in Mfn2 expression have an impact on MAM reorganization, perhaps 
through changes in the phospholipid composition in ER-mitochondrial contact sites. 
These observations also reveal that changes to Mfn2levels may alter the composition of 
tethers at ER-mitochondrial contact sites, and this may be dependent on the cell context. 
In addition, those data complement the observations that disruption of individual MAM 
components seem to be sufficient to alter phospholiid synthesis in disorders such as 
Alzheimer disease and Lenz-Majewski syndrome79-81.   
 
In contrast to the function of Mfn2, Mfn1 shows a broader phospholipid binding activity 
but it does not generate PE- or PC-rich domains. The N-terminal region (20 amino acid 
residues) of Mfn2 (not present in Mfn1) is key for PS specificity, as elimination of this 
region generates a mutant form of Mfn2 incorporating he capacities of Mfn1 and Mfn2, 
indicating a hybrid behavior. Further studies will be needed to understand the molecular 
basis for the PS binding and extraction activities of Mfn2.  
 
In conclusion, our data support the view that Mfn2 sustains PS transfer to the 
mitochondria for conversion to PE. The effects on phospholipid metabolism may 
explain the role of Mfn2 in the maintenance of MAMs and proper lipid metabolism and 
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ER homeostasis. Thus, we propose Mfn2 as a potential therapeutic target for 
counteracting the development of liver disease related to NASH and liver cancer.  
 
Experimental Procedures. 
Experimental Procedures see Supplemental Information.  
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FIGURE 1.  Mfn2 is reduced in NASH and liver-specific Mfn2 ablation in mice 
causes a NASH-like phenotype. A) Quantification of Mfn2 protein in liver biopsies 
from steatotic (NAS ≤3, n=7) and NASH (NAS ≥5, n=8) patients. B) Quantification of 
Mfn2 protein in liver from mice on chow diet (C) orhigh-fat diet (HFD) as a model of 
steatosis (n=4 mice per group). C) Representative H&E and Sirius red staining images 
in liver sections from 8-week-old C57Bl6/J mice fed ither a chow diet (C) or a 
methionine/choline-deficient diet combined with HFD and supplemented with 0.1% L-
methionine in drinking water (MCD) (scale bar, 200 µm). D) Triglyceride (TAG) levels 
in liver from mice on C and MCD diets (n=5 mice per group). E) Quantification of 
Mfn2 protein in liver from C (n=5) and MCD mice (n=4). F) Hepatic pro-inflammatory 
factors in control (C) and liver-specific Mfn2 KO (L-KO) mice measured by ELISA 
(n=8 mice per group). G) Hepatic TAG levels in C and L-KO mice (n=8–12 mice per 
group). H) Oleate incorporation into different lipid species in hepatocytes isolated from 
C and L-KO mice (n=4 mice per group, each experiment performed in triplicate). I) 
Representative Sirius red staining and TEM images in liver sections from 27-week-old 
C and L-KO mice fed a normal diet (scale bars, 200 µm in Sirius Red staining images, 
and 5 µm in TEM images). J) Hepatic expression of genes involved in collagen 
synthesis in C and L-KO mice (n=5 mice per group). K) Representative macroscopic 
images of liver from 24 month-old C and L-KO mice fd a normal diet, and 
quantification of liver tumors expressed as the mean of number of tumours in livers 
from 5 mice. In panel A, data are expressed as mean ± SD, and in the remaining panels 
as mean ± SE.  *p<0.05 vs.  control group in each case.  
 
FIGURE 2. Normalization of ER stress ameliorates inflammation and fibrosis but 
not lipid metabolism in L-KO mice. Control (C) mice were studied 5 days after tail 
vein injection of control LacZ adenoviruses (C+AdC) and L-KO mice were studied 5 
days after tail vein injection of control (LacZ) (L-KO+AdC, red bars) or BIP 
adenoviruses (L-KO+AdBIP, yellow bars) (n=4 mice per group). Data are expressed as 
values relative to control LacZ group (shown as a discontinuous line). A) 
Representative western blot of protein expression of hepatic ER stress markers. B) 
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Hepatic pro-inflammatory factors measured by ELISA. C) Plasma levels of IL-1β. D) 
Expression of genes involved in collagen synthesis. E) Hepatic TAG levels . F) Oleate 
incorporation into lipid species in isolated hepatocy es. Data are expressed as mean ± 
SE. Statistical analysis was performed by using one-way ANOVA followed by post-hoc 
t tests. *p<0.05 L-KO vs. C mice, $p<0.05 L-KO+AdBIP vs. L-KO+AdC mice.  
 
FIGURE 3. Mfn2 ablation alters hepatic phospholipid metabolism independently 
of ER stress. A) Hepatic phosphatidylcholine (PC) and phosphatidylethanolamine (PE) 
content measured by lipidomics in control (C) (n=11) and L-KO (n=13) mice. Data are 
expressed as fold-change vs. C mice. Significant compounds are shown in the heatmap 
(p<0.05) out of 128 phospholipids analyzed. B) Graphical scheme of phosphatidylserine 
(PS), phosphatidylethanolamine (PE) and PS synthesis in mitochondria-associated ER 
membranes (MAMs). C–E) 3H- L-serine incorporation into PS (C), PE (D), and 
phosphatidylcholine (PC) (E) in hepatic mitochondria-associated ER-enriched fractions 
from C and L-KO mice (n=5–7 mice per group). F) 3H- L-serine incorporation into PS, 
PE and PC in hepatic mitochondria-associated ER-enriched fractions from control (lacZ 
injected, C+AdC), L-KO (lacZ injected, L-KO+AdC, red bars), and L-KO (BIP 
injected, L-KO+BIP mice, yellow bars) (n=4 mice per group). Data are expressed as 
values relative to C+AdC group (shown as a discontinuous line). G) 3H-L-serine 
incorporation into PS, PE and PC in hepatic mitochondria-associated ER-enriched 
fractions from C+AdC, L-KO+AdC (red bars), and L-KO (Mfn2 injected, L-
KO+AdMfn2 mice, grey bars) (n=4 mice per group). Data re expressed as values 
relative to C+AdC group (shown as a discontinuous line). H) Representative western 
blot showing hepatic expression of PSS1, PSS2 and PEMT proteins levels in 8-week-
old C and L-KO mice (n=4 mice per group). I) Protein xpression of MAM proteins in 
liver from C and L-KO mice (n=4 mice per group). Data re expressed as mean ± SE. 
Statistical analysis was performed by using one-way ANOVA followed by post-hoc t 
tests.   *p<0.05 L–KO vs. C mice, $p<0.05 vs. L-KO+AdC mice.  
 
FIGURE 4.  Deficiency of hepatic phosphatidylserine synthase 1 and 2 phenocopies 
Mfn2 ablation. A) Quantification of hepatic protein expression of PSS1 and PSS2 5 
days after tail vein injection with control LacZ (C) or Ptdss1/Ptdss2 (KD) siRNA 
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adenoviruses (n=5 mice per group). B) Quantification f PSS1 protein in MAM 
fractions obtained from C or KD mice (n=5 mice per group). C) 3H-L-serine 
incorporation into PS and PE in hepatic mitochondria-associated ER-enriched fractions 
from C or KD mice (n=4 mice per group). D) Hepatic triglyceride (TAG) levels in C 
and KD mice (n=4 mice per group). E) Quantification of protein expression of hepatic 
ER stress markers in C and KD mice (n=4 mice per group). F) Hepatic expression of 
genes involved in inflammation in C and KD mice (n=5 mice per group). G) 
Quantification of Mfn2 protein in MAM fractions from C and KD mice. H) Scheme of 
PSS1 overexpression in mice. I) mRNA levels of Ptdss1 and Ptdss2 from control (lacZ 
injected, C+AdC), L-KO (lacZ injected, L-KO+AdC, red bars), and L-KO (Ptdss1 
injected, L-KO+Ptdss1, blue bars) mice (n=3–5 mice per group). J) 3H-L-serine 
incorporation into PS, PE and PC in hepatic mitochondria-associated ER-enriched 
fractions from C+AdC, L-KO+AdC (red bars), and L-KO+Ptdss1 mice (blue bars) 
(n=3–5 mice per group). K) Hepatic TAG levels in C+AdC, L-KO+AdC (red bars), and 
L-KO+Ptdss1 (blue bars) mice. L) Quantification of protein expression of hepatic ER 
stress markers in C+AdC, L-KO+AdC (red bars), and L-KO+Ptdss1 (blue bars) mice 
(n=3–5 mice per group). Data are expressed as values relative to C+AdC group (shown 
as a discontinuous line). Data are expressed as mean ± SE. Statistical analysis was 
performed by using one-way ANOVA followed by post-hoc t tests. *p<0.05 vs. C mice, 
$p<0.05 vs. L-KO+AdC mice. 
 
FIGURE 5. Mfn2 binds phosphatidylserine and generates phosphatidylserine-rich 
domains in membranes. A) Binding of Mfn2 protein immunoprecipitated from liver to 
different phospholipids on a Membrane Lipid StripTM. B) Binding of a truncated form 
of Mfn2 (1–613), expressed in liver and purified byaffinity chromatography, to 
phospholipids on a Membrane Lipid StripTM. C) 3H-L-serine incorporation into PS, PE 
and PC in hepatic mitochondria-associated ER-enriched fractions from mice injected 
with LacZ in control (C+AdC) and L-KO (L-KO+AdC, red bars) mice and with a Mfn2 
(1–613) adenovirus (L-KO+Mfn2 (1–613), blue bars) (n=4 mice per group). Data are 
expressed as values relative to the C+AdC group (shown as a discontinuous line). D) 
Representative Commassie-stained gel of the purification of Mfn2 (1–613) expressed in 
E. coli. E) Binding of Mfn2 (1–613) expressed in E. coli to different phospholipids on a 
Membrane Lipid StripTM. F) Representative western blot against Mfn2 after the 
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liposome flotation assay with different fluorescent (NBD) phospholipids. G) Scheme of 
the NBD-Phospholipid liposome extraction assay. H) Quantification of NBD-PS 
liposome extraction assay with Mfn2 (1–613) expressed in E. coli (n=6). I) Confocal 
microscopy images of liposomes in the absence or presence of Mfn2 (1–613), showing 
the formation of the NBD-PS rigid domain with Mfn2 (1–613). J) Kinetic FRET assay 
with NBD-PS and Rhod-PE to evaluate the capacity of Mfn2 (1–613) to dequench 
NBD-PS fluorescence from liposomes (n=6). Data are expressed as mean ± SE. 
Statistical analysis in panel H: *p<0.05 vs.  C $p<0.05 vs. L-KO+AdC. Statistical 
analysis in panel J was performed by using a two-way ANOVA (*p<0.0001). 
 
FIGURE 6. Phosphatidylserine binding and extraction activities of Mfn2 require 
an intact N-terminal region. A) Representative Commassie-stained gel of the 
purification of a short form of Mfn1 (1–592) express d in E. coli. B) Representative 
western blot against histidine showing Mfn1 protein after the liposome flotation assay 
with different non-fluorescent phospholipids. C) Quantification of NBD-PS liposome 
extraction assay with Mfn1 (1–592) expressed in E. coli (n=3). D) Quantification of 
NBD-PE extraction assay with Mfn1 (1–592) expressed in E. coli (n=3). E) Mfn2 and 
Mfn1 human sequence alignment. F) Representative Commassie-stained gel of 
purification of Mfn2 (21–613) expressed in E. coli. G) Representative western blot 
against histidine showing Mfn2 (21–613) protein after the liposome flotation assay with 
non-fluorescent phospholipids. H) Quantification of NBD-PS liposome extraction assay 
with Mfn2 (21–613) expressed in E. coli (n=3). I) Quantification of NBD-PE liposome 
extraction assay with Mfn2 (21–613) expressed in E. coli (n=3). Data are expressed as 
mean ± SE. *p<0.05 vs. C. 
 
FIGURE 7. Mfn2 re-expression improves the NASH phenotype in mice. A) 3H-L-
serine incorporation into PS, PE and PC in hepatic m tochondria-associated ER-
enriched fractions from control mice injected with AdC (null adenovirus) (C+AdC, 
white bars), MCD mice injected with AdC (MCD+AdC, blue bars), with AdMfn2 
(MCD+AdMfn2, red bars) or with AdBIP (MCD+BIP, yellow bars) (n=4 mice per 
group). B) Representative H&E and Sirius red staining images in liver sections from 
C+AdC, MCD+AdC, MCD+Mfn2 and MCD+BIP mice (scale bar, 200 µm). C) Hepatic 
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triglyceride (TAG) levels in C+AdC (white bars), MCD+AdC (blue bars), MCD+Mfn2 
(red bars) and MCD+BIP (yellow bars) mice (n=4 mice per group). D) Hepatic pro-
inflammatory factors and genes involved in collagen sy thesis in C+AdC (white bars), 
MCD+AdC (blue bars), MCD+Mfn2 (red bars) and MCD+BIP (yellow bars) mice (n=4 
mice per group). Data are expressed as the mean ± SE. Statistical analysis was 
performed by using one-way ANOVA followed by post-hoc t tests. *p<0.05 vs.  
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FIGURE S1. Mfn2 is downregulated in NASH. A) mRNA levels of Mfn2 in liver 
biopsies from NAS ≤ 3 (n=8) and NAS ≥ 5 subjects (n=8). B) Representative western blot 
of Mfn2 protein in liver biopsies from NAS ≤ 3 and NAS ≥ 5 subjects. C) Quantification 
of Mfn2 protein in liver biopsies from NAS ≤ 3 and NAS ≥ 5 subjects (n=20 per group). 
D) Quantification of Mfn1 protein in liver biopsies from NAS ≤ 3 and NAS ≥ 5 subjects 
(n=20 per group). E) Representative western blot of Mfn2 protein from mice on chow 
diet (C) or high-fat diet (HFD, model of steatosis). F) mRNA levels of pro-inflammatory 
markers from liver from mice on (C) or methionine/choline-deficient diet combined with 
high-fat diet and supplemented with 0.1% L-methionine in drinking water (MCD) (n=4 
mice per group). G) mRNA levels of TGF from C and MCD mice (n=4 mice per group). 
H) Representative western blot of Mfn2 protein from C and MCD mice (n=5 mice per 
group). I) Quantification of Mfn1 protein levels from C and MCD mice (n=4 mice per 
group). Data in A–D are expressed as mean ± SD. Data in E–I are expressed as mean ± 
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FIGURE S2. Phenotype of liver-specific Mfn2 knockout mice. Eight week-old control 
(C) and L-KO mice were used unless stated otherwise. Control mice are represented as 
open bars and L-KO mice as red bars. A, B) Plasma levels of pro-inflammatory markers 
(n=8–12 mice per group). C) Hepatic expression of pro-inflammatory genes (n=8–12 
mice per group). D) Body weight of C and L-KO mice (n=8–12 mice per group). E) Food 
intake of C and L-KO mice (n=8–12 mice per group). F–H) Plasma concentrations of 
lipid metabolites (n=8–12 mice per group). I) Oleate oxidation in isolated hepatocytes 
from C and L-KO mice (n=6 mice per group; each experiment performed in triplicate). J) 
mRNA levels of genes involved in lipid metabolism  (n=8–12 mice per group). Data are 

































































































































































FIGURE S3. Mfn2 ablation causes apoptosis, increased cell growth, and liver 
cancer. A) Representative western and protein quantification of apoptosis markers in 
liver from control (C) and L-KO mice (n=4 mice per group). B) Representative images 
(scale bar, 100 m) and quantification of cleaved caspase 3 in liver sections from C and 
L-KO mice (n=6 mice per group). C) Representative images and quantification (scale bar, 
100 m) of Ki67 in liver sections from C and L-KO mice (n=6 mice per group). D) Mean 
tumor volume measured in livers from 24-month-old C and L-KO mice (n=5 mice per 
group). E) Representative images (scale bar, 200 m) of H&E, H2AX (DNA damage 
marker) and Ki67 (proliferation marker) staining in liver sections from C and L-KO mice 
acutely treated with diethylnitrosamine (DEN) (50 mg/kg for 48 h, n=5 mice per group). 
F,G) Quantification of H2AX and Ki67 in liver sections from 12 week-old C and L-KO 
mice acutely treated with a high dose of diethylnitrosamine (DEN) (n=5 mice per group). 
H) Representative liver macroscopic images from C and L-KO mice treated for 7 months 
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FIGURE S4. Mfn2 re-expression restores normal liver metabolism in L-KO mice. 
Control mice were examined 5 days after tail vein injection of control LacZ adenoviruses 
(C+AdC) and L-KO mice were studied 5 days after tail vein injection of control (LacZ) 
(L-KO+AdC, red bars) or Mfn2 adenoviruses (L-KO+Mfn2, grey bars) (n=4 mice per 
group).  Data are expressed as values relative to C+AdC group (shown as a discontinuous 
line). A) Representative western blot of Mfn2 protein in liver B) Hepatic levels of hepatic 
pro-inflammatory factors measured by ELISA. C,D) Plasma levels of the pro-
inflammatory factors IL-1β and TNFα. E) Hepatic expression of genes involved in 
collagen synthesis. F) Triglyceride content in liver. G) Hepatic expression of pro-
inflammatory genes. H) Oleate oxidation in isolated hepatocytes (n=4 mice per group, 
each experiment performed in triplicate). I) Representative western blot and 
quantification of hepatic ER stress markers. Data are expressed as mean ± SE. Statistical 
analysis was performed by using one-way ANOVA followed by post-hoc t tests. *p<0.05 

















































































































































































FIGURE S5.  Effect of normalization of ER stress in L-KO mice. Control mice were 
studied 5 days after tail vein injection of control LacZ adenoviruses (C+AdC) and L-KO 
mice were studied 5 days after tail vein injection of control (LacZ) (L-KO+AdC, red bars) 
or BIP adenoviruses (L-KO+AdBIP, yellow bars). Data are expressed as values relative 
to C+AdC group (shown as a discontinuous line). A) Quantification of hepatic ER stress 
markers (n=4 mice per group). B) Hepatic mRNA expression of pro-inflammatory genes 
(n=4 mice per group). C) Quantification of cleaved caspase 3 in liver sections (n=4 mice 
per group). D) Representative images (scale bar, 100 m) and quantification of the 
proliferation marker Ki67 in liver sections (n=4 mice per group). E) Oleate oxidation in 
isolated hepatocytes (n=4 mice per group, each experiment performed in triplicate). F) 
Hepatic hydrogen peroxide levels (n=4 mice per group). Data are expressed as mean ± 
SE. Statistical analysis was performed by using one-way ANOVA followed by post-hoc 
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FIGURE S6. Mfn2 ablation alters phospholipid metabolism and MAMs protein 
composition. Multivariate analyses revealed a specific lipidomic signature for KO mice 
compared with controls for both mitochondria (MIT) (A, B, C) and MAM (D, E, F). A, 
D) Partial Least Squares Discriminant Analyses (PLS-DA) showed a good clusterization 
of both groups according to their lipidomic profile. B, E). Variable Importance in 
Projection (VIP) scores represent those metabolites that contribute most to the PLS-DA 
model. C, F). Hierarchical clustering analyses using 25 metabolites with lowest p-values 
(Student’s t-test) indicate a perfect clusterization between groups. Unknown identities are 
represented as exact mass@retention time. G) Hepatic PEMT protein expression in 8-
week-old control and L-KO mice (n=4). H) Quality control of subcellular fractionation 
of livers obtained from 8-week-old control and L-KO mice.  I) Abundance of protein 
markers in MAMs fractions obtained from control and L-KO mice (n=4). Data are 
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FIGURE S7.  Effect of ER-mitochondrial tethering in L-KO mice. Control (C) and 
L-KO livers were studied 5 days after tail vein injection of AdC or Adlinker (n=4 mice 
per group). A) Hepatic expression of RFP protein in C and L-KO mice after injection 
with control adenoviruses (C+AdC, L-KO+AdC) or with adenoviruses encoding a 
synthetic linker (C+AdLinker, L-KO+AdLinker). B) 3H-L-serine incorporation into PS, 
PE and PC in hepatic mitochondria-associated ER-enriched fractions from C+AdC, 
L+KO+AdC (red bars) and L-KO+AdLinker (yellow bars). Data are expressed as values 
relative to C+AdC group (shown as a discontinuous line). C) Hepatic triglyceride levels 
from C+AdC, L+KO+AdC (red bars) and L-KO+AdLinker (yellow bars). D, E) Hepatic 
ER stress markers and quantification from C+AdC, L+KO+AdC (red bars) and L-
KO+AdLinker (yellow bars). F) Representative western blot and quantification of hepatic 
PSS1 and PSS2 protein expression in C+AdC, L+KO+AdC (red bars) and L-
KO+AdLinker (yellow bars) mice. Data are expressed as mean ± SE. Statistical analysis 
was performed by using one-way ANOVA followed by post-hoc t tests. *p<0.05 vs. 
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FIGURE S8. Effects of hepatic deficiency of phosphatidylserine synthase 1 and 2. A) 
Representative western blot of PSS1 and PSS2 protein and PSS2 protein quantification 
in 8-week-old mice 5 days after tail vein injection with control LacZ (C) or Ptdss1 siRNA 
adenoviruses (PSS1KD) (n=4 mice per group). B) Representative western blot of PSS1 
and PSS2 protein levels and PSS1 quantification in mice 5 days after tail vein injection 
with control LacZ (C) or Ptdss2 siRNA adenoviruses (PSS2KD) (n=4 mice per group). 
C) Hepatic expression of PSS1 and PSS2 protein in control mice 5 days after tail vein 
injection with control LacZ (C) or Ptdss1/Ptdss2 siRNA adenoviruses (KD) (n=4 mice 
per group). D) Oleate incorporation into lipid species in isolated hepatocytes from C 
(open bars) and KD (blue bars) mice (n=4 mice per group). E) Western blot of hepatic 
ER stress protein markers in C and KD mice (n=4 mice per group). F) mRNA expression 
of hepatic fibrosis markers in C and KD mice (n=4 mice per group). G) Hepatic levels of 
pro-inflammatory factors in C and KD mice measured by ELISA (n=4 mice per group). 
H) Oleate oxidation in isolated hepatocytes from C and KD mice (n=4, each experiment 
performed in triplicate). I) Hepatic H2O2 levels in C and KD mice  (n=4 mice per group). 
J) Quality control of the subcellular fractionation of liver obtained from C and KD mice.  
K–L) Representative western blot and quantification of protein markers in MAM 
fractions obtained from C and KD mice. M) Representative western blot of hepatic ER 
stress protein markers from control mice injected with lacZ adenoviruses (C+AdC), and 
L-KO mice injected either with lacZ (L-KO+AdC, red bars), or Ptdss1 adenoviruses (L-
KO+AdPtdss1, blue bars) (n=3–5 mice per group). Data are expressed as mean ± SE. 
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FIGURE S9. Mfn2 specifically extracts PS from membranes. A) Representative 
western blot against histidine showing Mfn2 (1–613) after the liposome flotation assay 
with different non-fluorescent phospholipids using Mfn2 (1–613) purified from E. coli. 
B) Quantification of NBD-PE liposome extraction assay with Mfn2 (1–613) expressed in 
E. coli (n=3). C) Confocal microscopy images of NBD-PC/Rhod-PE liposomes in the 
absence or presence of Mfn2 (1–613).  D) Kinetic FRET assay with NBD-PE and Rhod-
PE to evaluate the capacity of Mfn2 (1–613) to dequench NBD-PE from liposomes (n=6). 
E) Kinetic FRET assay with TOPFluor-PS and doxyl-PC to evaluate the capacity of Mfn2 
(1–613) to dequench TOPFluor-PS from liposomes (n=4). F) Kinetic FRET assay with 
TOPFluor-PE and doxyl-PC to evaluate the capacity of Mfn2 (1–613) to dequench 
TOPFluor-PE from liposomes (n=4). Data are expressed as mean ± SE. Statistical 
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FIGURE S10. Mfn2 re-expression improves the phenotype in a NASH mouse model. 
A) Western blot showing re-expression of Mfn2 in mice on chow diet (C) and 
methionine/choline-deficient diet combined with high-fat diet and supplemented with 
0.1% L-methionine in drinking water (MCD) (n=4 mice per group). B) Western blot of 
BIP overexpression in C and MCD mice (n=4 mice per group). C) Quantification of Mfn2 
protein in liver from control mice injected with AdC (null adenovirus) (C+AdC, white 
bars), MCD mice injected with AdC (MCD+AdC, blue bars), AdMfn2 (MCD+AdMfn2, 
red bars) or AdBIP (MCD+BIP, yellow bars) (n=4 mice per group). D) Quantification of 
hepatic ER stress protein markers from C+AdC, MCD+AdC, MCD+AdMfn2 and 
MCD+AdBIP mice. Data are expressed as mean ± SE. Statistical analysis was performed 
by using one-way ANOVA followed by post-hoc t tests. *p<0.05 vs.  C+AdC, $p<0.05 




























Supplementary Methods.  
 
Human liver biopsies 
Liver biopsies were obtained from NAFLD patients undergoing bariatric surgery; liver 
biopsies from normal individuals were not collected due to ethical issues.  Biopsies were 
processed conventionally for diagnostic purposes, histological grading, and staging, as 
described previously (Ferreira et al., 2011). In particular, all liver specimens were 
evaluated by an experienced pathologist, blinded to clinical data, and following the 
NAFLD histology scoring system.  The severity of steatosis was graded from 0 to 3, 
inflammation from 0 to 3, hepatocellular ballooning from none to many, and fibrosis from 
0 to 4.  Each liver specimen was assessed for the presence or absence of NASH by pattern 
recognition, and for NAFLD activity score (NAS score), defined as the sum of steatosis, 
inflammation and hepatocyte ballooning. Patients with a NAS score of ≥5 were 
considered as likely to have NASH (Kleiner et al., 2005; Neuschwander-Tetri and 
Caldwell, 2003).  
All patients gave written informed consent. The study protocols conformed to the Ethical 
Guidelines of the 1975 Declaration of Helsinki, revised in 2000, as reflected in a priori 
approval by the Hospital de Santa Maria (Lisbon, Portugal), by the Hospital Sant Joan de 
Reus (Institutional Review Board, project code: INFLAMED/15-04-30/4prog7) and 
Human Ethics Committee.  
 
Animal care, generation of animal models, and diet treatments  
All animal work was approved and conducted according to guidelines established. This 
project has been assessed favourably by the Institutional Animal Care and Use Committee 
from Parc Cientific de Barcelona (IACUC-PCB) and the IACUC considers that the 
above-mentioned project complies with standard ethical regulations and meets the 
requirements of current applicable legislation (RD 53/2013 Council Directive; 
2010/63/UE; Order 214/1997/GC). Control and KO mice were littermates. Mice were 
kept under a 12 h dark-light period and provided a standard chow-diet and water ad 
libitum. Eight-week-old C57Bl6/J males were fed a standard or a high-fat diet for 3 weeks 
(60% calories from fat, D12451 and D12492 from Research Diets, New Brunswick, 
USA).  To MCD experiments: Eight-week-old C57Bl6/J males were fed a standard of 
methionine choline deficient diet combined with high fat diet (A06071305 MCD with 




water during 3 weeks. At the times indicated in the figure legends, mice were anesthetized 
using isoflurane and sacrificed by cervical dislocation. Tissues used for RNA purification, 
protein extraction or histology were prepared as published (Liesa et al., 2008; Soriano et 
al., 2006). 
DEN treatment 
To further characterize the protector effect of Mfn2 in liver, we assessed an acute 
treatment with a high dose of the carcinogen Diethylnitrosamine (DEN). Then, we treated 
16 week-old control and L-KO mice for 48h with a single injection of DEN at 50 mg/kg. 
Liver sections from DEN-treated or untreated mice were stained with anti-Ki67 and anti-
γH2AX as well as Hematoxilin and Eosin staining. DNA damage and compensatory 
proliferation were assessed by microscopy on paraffin-embedded sections (Herranz et al., 
2010). In addition, to corroborate the susceptibility of Mfn2 ablation to develop liver 
cancer we used DEN combined with high fat diet (HFD) to induce liver cancer in mice 
(Herranz et al., 2010; Wu et al., 2010). To this end, 5 days-old mice were injected with a 
single dose of DEN (5 mg/kg) and put on HFD immediately after weaning. After 7 month 
of treatment the mice were sacrificed and tumors in each liver lobule were counted and 
measured with a caliper.  
 
Plasma measurements. Plasma concentrations of insulin, NEFA, ketone bodies, 
triglycerides, cholesterol, IL6, TNF and IL-1 (Abnova) were measured following the 
manufacturer’s instructions.  
 
Liver subcellular fractionation and MAM purification  
Liver fractions were purified as previously described (Wieckowski, Giorgi et al. 2009; 
Tubbs  2014).  Briefly, after homogenization of about 1 g of liver with a Teflon potter in 
Isolation Buffer (225 mM mannitol, 75 mM sucrose, 0.5% BSA, 0.5 mM EGTA and 30 
mM Tris-HCl, pH7.4), cellular debris and nucleus were removed with two centrifugations 
at 740 x g  for 5 min. A small volume of supernatant was taken, this was called the 
homogenate fraction. Crude mitochondria were collected by centrifugation at 9,000 x g 
for 10 min, and the pellet was resuspended in Mitochondria Buffer (MB) (250 mM 
mannitol, 5 mM HEPES and 0.5 mM EGTA, pH 7.4). The supernatant was conserved for 




mitochondria fraction with a Percoll medium centrifugation at 95,000x g for 30 min in a 
SW40 rotor (Beckman). Pure mitochondria (pM) at the bottom of the tube were collected, 
washed twice by centrifugation at 6,300 x g for 10 min, and resuspended in RIPA buffer. 
MAMs were collected from a white band in the middle of the tube. They were then diluted 
in MB and centrifuged at 6,300 x g for 10 min to remove mitochondrial contamination, 
pelleted with a 1-h centrifugation at 100,000 x g in a 70Ti rotor (Beckman), and finally 
resuspended in MB. The ER was purified by two centrifugations at 20,000 x g and 
100,000 x g for 30 min and 1 h respectively. Finally, the ER pellet was washed once in 
MB with a 10 min centrifugation at 9,000 x g and resuspended in RIPA buffer. In order 
to estimate the amount of each fraction within the liver, proteins were determined using 
the PierceTM BCA Protein Assay kit (Thermo scientific). Purification yield was 
expressed as mg of protein/g of liver and the amount of MAM was then normalized by 
the amount of pure mitochondrial (pM) protein. 
 
 
Hepatocyte isolation  
Collagenase perfusion was used to isolate hepatocytes from male control and liver-
specific Mfn2 knockout mice (25–28 g), as described (Massague and Guinovart, 1977). 
Cells were suspended in Dulbecco's Modified Eagle's Medium (DMEM), supplemented 
with 10 mM glucose, 10% (v/v) fetal bovine serum (FBS), 100 nM insulin (Sigma), and 
100 nM dexamethasone (Sigma), and then seeded at a final density of 4 × 106 cells/cm2 
onto 60-mm diameter plastic plates treated with 0.001% (w/v) collagen solution (Sigma). 
Media were replaced with fresh M99 media-free serum, 1% BSA, and cells were 
incubated for 12–14 h.  
 
Adenoviral transduction  
The following adenoviruses were used in this study: Ad-LacZ, Ad-Mfn2-Histidine 
(encoding for a truncated form of Mfn2= Mfn2 (1-613)) (Pich et al., 2005; Segalés et al., 
2013). Ad-Mfn2 was cloned by recombination into the pAdeno-CMV-V5 adenoviral 
vector (Invitrogen) using the Gateway system. Adenoviruses were generated by 
transfection of the adenoviral expression vectors in human embryonic kidney cell line 
(HEK 293). The adenoviruses generated were then amplified at the Unitat de Producció 
de Vectors Virals-CBATEG (Universitat Autònoma de Barcelona).  Ad-Ptdss1, Ad-




Dr. Gokan Hotamisligil, Harvard University), and Ad-BIP (a gift from Dr. Jennifer 
Rieusset, INSERM Lyon) were also used.  
Cells: Isolated hepatocytes were grown in DMEM 10% FBS. On the day of the 
experiment, they were infected at a multiplicity of infection (moi) of 50 pfu/cell, and all 
the experiments were performed 48 h after infection. After infection, cells were incubated 
for a further 16 h in infection medium before performing the experiment.  
Animals: Adenovirus transductions of mice were performed between 8 and 10 weeks of 
age, and 1 × 109 IFU/mouse were injected via the tail vein. Livers were isolated after 5 
days of adenovirus infection. 
 
Oleate -oxidation in isolated hepatocytes 
Isolated hepatocytes were pre-incubated for 30 min at 37°C in 2 ml of Krebs-Ringer 
bicarbonate Hepes buffer containing 2% bovine serum albumin (fatty acid free-BSA; 
Sigma, St Louis, MO, USA) and 5 mmol/l glucose (incubation medium). The medium 
was gassed continuously with 95% O2, 5% CO2. The medium was then removed and 
replaced by 2 ml of fresh incubation medium, containing 1 μCi/ml D-[U]-14C-Oleate 
(Amersham Biosciences). The hepatocytes were incubated for 180 min at 37°C. The test 
plates were hermetically sealed with parafilm with a centre well that contained a piece of 
filter paper saturated with 200 μl of 1M KOH (Sebastián et al., 2007). At the end of the 
incubation, the medium was acidified with 0.3 ml of 0.5N H2SO4 and gaseous 
14CO2 
released after the acidification was trapped in the filter paper. The vials were incubated 
at 37°C for 60 min, and the filter papers were removed and transferred to vials for liquid 
scintillation counting (Sebastián et al., 2007). 
 
Oleate incorporation into lipids in isolated hepatocytes 
Isolated hepatocytes were pre-incubated for 30 min at 37°C in 2 ml of Krebs-Ringer 
bicarbonate Hepes buffer containing 2% bovine serum albumin (fatty acid free-BSA; 
Sigma, St Louis, MO, USA) and 5 mmol/l glucose (incubation medium). The medium 
was gassed continuously with 95% O2, 5% CO2. The medium was then removed and 
replaced by 2 ml of fresh incubation medium, containing 1 μCi/ml D-[U]-14C-Oleate 
(Amersham Biosciences). The hepatocytes were incubated for 16 h at 37°C (95% O2, 5% 
CO2). At the end of the incubation, the medium was removed and plates were washed 3 
times PBS 1X. Lipids were extracted and resolved in a thin layer chromatograph as 





Histological sample preparation and analysis 
For light microscopy, sections were stained with hematoxylin and eosin. For neutral 
lipids, liver slices were stained with Oil Red O following Roy Ellis (Woodville, South 
Australia).  For the preparation of livers for electron microscopy, samples were sectioned 
in small fragments with a razor blade to 1 mm and then fixed in 2.5% glutaraldehyde 2% 
paraformaldehyde solution 0.1 M at 4 C for 2 h. The samples were washed three times 
with 0.1 M phosphate buffer. Following post-fixation in 1% osmium tetroxide in 0.1 M 
phosphate buffer at 4ºC for 2 h, they were then washed with highly pure water and kept 
overnight in 0.1 M phosphate buffer. Afterwards, samples were dehydrated at 4ºC under 
shaking in graded solutions of acetone (50%, 70% and 90%) in highly pure water. They 
were then gradually infiltrated with Eponate 12 Resin (TED PELLA 18010), and 
polymerization of the resin was processed for 48 h at 60ºC. Thin sections (50-nm) were 
cut using a Leica EM UC6 (Leica, Vienna) and mounted on bare 200-mesh copper grids. 
Sections were stained with uranyl acetate 2% for 30 min, then washed with highly pure 
water and finally incubated for 5 min with lead citrate and air-dried. Soleus samples were 
prepared at equal lengths along the long axis of the muscle. Sample sections were viewed 
on an FEI CM-12 transmission electron microscope. 
 
Western blotting and immunoprecipitation assays  
Homogenates for Western blot analyses were obtained from either cell cultures or tissues. 
Cells were collected in ice-cold PBS 1X and homogenized with a douncer in lysis buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 2 mM EDTA, 2 mM sodium 
ortovanadate, 50 mM NaF, 20 mM sodium pyrophosphate and protease inhibitors cocktail 
tablet, Roche) and centrifuged at 700 x g for 10 min to remove nuclei, cell debris, and 
floating cells. Tissues samples were homogenized in 10 volumes of lysis buffer using a 
polytron. Homogenates were rotated for 1 h at 4ºC in an orbital shaker and centrifuged at 
13,000 rpm for 15 min at 4ºC. Proteins from total homogenates were resolved in 10% or 
15% acrylamide gels for SDS-PAGE and transferred to Immobilon membranes 
(Millipore). The following antibodies were used: Mfn2, p-IRE1 and IRE1(1/1000, 
Abcam), p-eIF2α, eIF2α, BiP, p-PERK, PERK, pJNK, JNK (1/1000, Cell Signaling), 
CHOP, Ptdss1 and Ptdss2 (1/1000, Santa Cruz), ATF6 (1/1000, Imgenex), β-actin 




were detected by the ECL method (Enrique-Tarancon et al., 2000) and quantified by 
scanning densitometry.  
 
RNA extraction and real-time PCR 
Mice were killed by cervical dislocation, and tissues were immediately frozen for RNA 
isolation.  RNA from liver tissues was extracted using a protocol combining TRIzol 
reagent (Invitrogen, Carlsbad Ca, USA) and RNAeasy® minikit columns (Qiagen, 
Alameda, CA, USA), following the manufacturer’s instructions. RNA was reverse-
transcribed with the SuperScript RTIII kit (Invitrogen, Carlsbad Ca, USA). PCRs were 
performed using the ABI Prism 7900 HT real-time PCR machine (Applied Biosystems, 
USA) and the SYBR® Green PCR Master Mix or the Taqman Probes 20X (Applied 
Biosystems, USA). All measurements were normalized to β-actin and GAPDH. 
 
 
Hepatic triglyceride measurements 
Levels of mouse liver triglycerides were quantified using the Triglyceride Determination 
Kit TRO100 with appropriate standards (Sigma-Aldrich, St. Louis, MO). Frozen liver 
samples were weighed, put into 2 ml of a chloroform:methanol mixture (2:1, v/v), and 
incubated for 2 h at room temperature with occasional shaking. Following the addition of 
0.2 volumes of water, vortexing, and centrifuging at 2,500 x g, the lower phase containing 
the lipids was collected and dried under vacuum in a rotary evaporator for 5–6 h. The 
dried pellets were resuspended in the reaction buffer provided in the kit. Results were 
expressed as mg/g tissue. 
 
Lipidomic analysis from liver 
Lipidomic analysis was done as described previously (Kotronen et al., 2010; Nygren et 
al., 2011). Briefly, liver samples were cryo-homogenized (Covaris, CryoPrep CP02, MA) 
and weighed (5 mg). An aliquot (20 µL) of an internal standard mixture containing 
PC(17:0/0:0), PC(17:0/17:0), PE(17:0/17:0), PG(17:0/17:0)[rac], Cer(d18:1/17:0), 
PS(17:0/17:0), PA(17:0/17:0) (Avanti Polar Lipids, Alabaster, AL), 
MAG(17:0/0:0/0:0)[rac], DAG(17:0/17:0/0:0)[rac] and TAG(17:0/17:0/17:0) was added 
to the sample, and the lipids were extracted using a mixture of HPLC-grade chloroform 




µL) was collected and 20 µL of an internal standard mixture containing labeled PC 
(16:1/0:0-D3), PC(16:1/16:1-D6) and TAG(16:0/16:0/16:0-
13C3) was added.   
Lipid extracts were analyzed on a Waters Q-Tof Premier mass spectrometer combined 
with an Acquity Ultra Performance LCTM (UPLC). The column (at 50°C) was an 
Acquity UPLCTM BEH C18 1 × 50 mm with 1.7-μm particles. The solvent system 
included A. ultrapure water (1% 1 M NH4Ac, 0.1% HCOOH) and B. LC/MS grade 
acetonitrile/isopropanol (5:2, 1% 1M NH4Ac, 0.1% HCOOH). The gradient started from 
65% A / 35% B, reached 100% B in 6 min and remained there for the next 7 min. The 
flow rate was 0.2 ml/min and the injected amount was 1.0 μl (Acquity Sample Organizer). 
Reserpine was used as the lock spray reference compound. The lipid profiling was carried 
out using ESI+ mode, and the data were collected at mass range of m/z 300–1200 with a 
scan duration of 0.2 sec. The data were processed using MZmine software version 6.0 
(Katajamaa et al., 2006; Pluskal et al., 2010) and normalized using lipid class-specific 
internal standards. Lipid species identification was done using an internal spectral library 
or tandem mass spectrometry. 
 
QTOF-based untargeted lipidomics of liver subcellular fractionation 
For protein precipitation three volumes of acetone were added to each sample (containing 
100 µg of protein). After acetone addition the samples were vortexed for 10 seconds, 
incubated at 4ºC for 30 min and centrifuged at 100g, at 4ºC for 10 minutes. Then, the 
supernatant was recovered and evaporated using a Speed Vac (Thermo Fisher Scientific, 
Barcelona, Spain).  
After supernatant evaporation, 250 µl of methanol were added and vortexed for 10 s. 
Then, 500 µl of chloroform (containing internal standard) were added and vortexed for 
10 s. Finally, 200 µl of KCl 0.7% were added and vortexed for 10 s and samples 
centrifuged at 1000 g at 4 °C for 15 min. The chloroform phase (lower) was recovered in 
a glass tube and aliquoted in chromatographic vials.  
For LC-Q-TOF-based lipid molecular species analyses, lipid extracts were subjected to 
liquid chromatography-mass-spectrometry using a HPLC 1290 series coupled to ESI-Q-
TOF MS/MS 6520 (Agilent Technologies, Barcelona, Spain) as previously described 
(Sandra et al.). Four microliters of lipid extract were injected onto an XBridge BEH C18 




80 °C. The mobile phases, delivered at 0.5 ml/min, consisted of ammonium formate 
(20 mM at pH 5) (A) and methanol (B). The gradient started at 50% B and reached 70% 
B in 14 min and was followed by a slow gradient of 70–90% B over 50 min and an 
isocratic separation at 90% B for 15 min. The mobile phase B subsequently reached 100% 
over 5 min and was maintained for an additional 5 min. Data were collected in positive 
electrospray ionization-TOF operated in full-scan mode at 100–3000 m/z in an extended 
dynamic range (2 GHz) (MassHunter Data Adquisition Sofware, Agilent Technologies, 
Barcelona, Spain), using N2 as nebulizer gas (5 L/min, 300 °C). The capillary voltage was 
3500 V with a scan rate of 1 scan/s. 
MassHunter Qualitative Analysis Software (Agilent Technologies, Barcelona, Spain) to 
obtain the molecular features of the samples, representing different, co-migrating ionic 
species of a given molecular entity using the Molecular Feature Extractor (MFE) 
algorithm (Agilent Technologies, Barcelona, Spain) (Jové et al., 2013). MassHunter Mass 
Profiler Professional Software (Agilent Technologies, Barcelona, Spain) and 
Metabolanalyst Software (Xia et al. 2016; Chong et al., 2018) was used to perform a non-
targeted lipidomic analysis over the extracted features. Only those features with a 
minimum abundance of 5000 counts and 2 ions as a minimum were selected. After that, 
the molecular characteristics in the samples were aligned using a retention time window 
of 0,1% ± 0,25 min and 20,0 ppm ± 2,0 mDa. Quality control-based correction was 
performed in order to correct the sample intensities according to injection order. A 
LOESS regression was performed for each QC metabolite, using polynomials of second 
degree and with an optimum smoothing parameter each time. Sample values were 
predicted and the relation between real values and predicted values was obtained, based 
on (Broadhurst  et al. 2018; Dunn et al. 2011). To avoid background, only common 
features (found in at least 70% of the samples of the QC) were taken into account to 
correct for individual bias. Multivariate statistics (Partial Least Squares Discriminant 
Analysis (PLS-DA) and Hierarchical Analyses) were done using Metaboanalyst software 
(Xia et al. 2016; Chong et al., 2018). Variable importance in projection (VIP) score was 
calculated using Metaboanalyst software [72, 73]. The masses with an important weight 
defining PLS-DA model and Hierarchical analyses as well as those  masses representing 
significant differences by Student T-Test (p < 0.05), defined by exact mass and retention 
time, were searched against the LIPID MAPS database (accuracy < 20 ppm) (Fahy et al., 




added. Finally, identities were confirmed by MS/MS by checking the MS/MS spectrums 
using LipidBlast software (Kind et al., 2013) and LipidMatch, a R-based tool for lipid 
identification (Koelmel et al., 2016). 
 
3H- L-serine incorporation into phospholipids in subcellular fractions 
Liver was homogenized (use Teflon-glass homogenizer) in Isolation Buffer (225mM 
Mannitol, 25mM Hepes-KOH, 1mM EGTA, pH7.4 add protease inhibitors tripsins and 
chimotripsins) at a ratio of 4 ml of IB for every gram of tissue. The homogenate was 
pelleted for 10 min at 1,500 x g at 4°C. SPN was transferred to a new tube and pelleted 
again under the same conditions. SPN was transferred again to a new tube and pelleted at 
13,000 x g for 20 min at 40C. This new pellet contained the crude mitochondrial fraction 
and was used to measure lipid transfer because it contains mitochondria and ER-MAM. 
The SPN contained the ER fraction, which was pelleted at 100,000 x g for 1 h at 40C. 
This pellet was used as a control in the assay. 1 mg of the fraction was pelleted again and 
resuspended in 200 l of Ptdser assay buffer (25 mM Hepes-KOH, 10 mM CaCl2 adding 
0.4 mM of 3Hser (20–30 ci/umol) pH 7.4). The mixture was incubated for 45 min at 
37oC and the reaction was stopped by adding 3 volumes of chloroform: MeOH (2:1). The 
lipids were extracted using the Folch Method, dried by N2, and run in a TLC as reported 
(Area-Gomez, 2014; Area‐Gomez et al., 2012). 
 
Mfn2 imunoprecipitation for phospholipid binding assays 
Liver from control mice was homogenized in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
1 mM EDTA, 1% Triton X-100, 2 mM sodium ortovanadate, 50 mM NaF, 20 mM sodium 
pyrophosphate and 1% SDS, pH 7.4. Protease inhibitors: Pepstatin A 2 uM, Leupeptin 2 
uM, PMSF 1 mM or one tablet from Roche per 10 ml of fresh buffer added. These 
conditions cause dissociation of Mfn2 from other potential binding partners including 
lipid species. 
The lysate was centrifuged for 10 min at 10,000 x g at 4ºC. The supernatant was warmed 
at 95ºC for 5 min. Supernatant was diluted 10 times with homogenization buffer without 
SDS and placed onto 50% Protein G-Agarose beads (30ul). 10 ul of Mfn2 ab or IgG was 
added and the mixture was incubated O/N at 4ºC on the roller. Next day, washes were 
done with 300–500 ul washing buffer (5 times). Then protein was extracted using glycine 




concentration was determined by the BCA Pierce assay, and the protein was used in fresh 
to assay the lipid strips. A small aliquot of protein was used for Western blotting. 
 
Purification of a short Mfn2 (1-613) for phospholipid binding assays 
Liver Mfn2 KO mice were injected with 1X109 pfu/bodyweight Ad-Mfn2-Histidine 
through the  tail vein; the adenovirus was used as previously reported (Segalés et al., 
2013). Injected mice were left in ad libitum conditions for adenoviral expression. After 5 
days mice were sacrificed and liver was extracted and immediately frozen in liquid 
nitrogen and stored at -80ºC until the assay was performed. Liver was homogenized in 
lysis buffer (25 mM Imidazol, 300 mM NaCl, 1% Triton X-100, 100 mM NaPO4, 1 mM 
Na3VO4, 50 nM calyculin A and EDTA-free complete pH 7.5 and 1% SDS) and put to 
rotate for 1 h at 4ºC. The lysate was centrifuged at 10,000 x g for 10 min at 4ºC. Then the 
supernatant was warmed to 95ºC for 5 min. The supernatant was then diluted ten times 
with lysis buffer and incubated with Ni-NTA beads  (previously equilibrated with lysis 
buffer without SDS). The mixture was incubated O/N at 4ºC under rotation. Next day, the 
beads were washed 5 times with washing buffer (50 mM Imidazol, 500 mM NaCl and 1 
mM Na3VO4, pH 7.5). At the end elution buffer (250 mM Imidazol, 300 mM NaCl, pH 
7.5) was added and the mixture was put into the thermomixer for 15 min at 25ºC and 1150 
rpm. Protein concentration was determined by the BCA Pierce assay, and the protein was 
used in fresh to assay the lipid strips. A small aliquot of protein was used for Western 
blotting. 
 
Purification of Mfn2 (1-613), Mfn1(1-592) and Mfn2(21-613) expressed in E.coli. 
100ng of cut vector pOPINI and 100ng of insert were used to clone the Mfn2(1-613) or 
Mfn1(1-592) or Mfn2(21-613) form by InFusion, according to manufacturer’s 
instructions. For all constructs the plasmids were transformed in Rosetta cells. Briefly, 
transform 5ul of each infusion reaction, and the equivalent amount of the controls. Plate 
100ul of settled cells,cb+iptg+xgal antibiotics, and leave ON at 37ºC. Lysis Buffer: 1% 
SDS +300mM NaCl+20mM Imidazole+1mM NaVO4+1.4mM KCl. Wash Buffer: 
500mM NaCl+40mM Imidazole. Elution Buffer: 300mM NaCl+250mM Imidazole. Each 
2ml pellet was resuspended in 200ul of Lysis Buffer then sonicated for  2x10’’ at 20%. 
The homogenate was incubated in an ice-water bath 30’. Spin 20’ at 20000g at 4ºC. SN 
was transferred to a new tube CRX (200ul). To magnetic niquel beads: Bind 2 * 100ul 




flow through samples. Add 100ul of each Wash Buffer to the beads, bind for 5’ shaking 
at RT. Bind beads to the magnets and collect Washes 1. Repeat this wash again, and 
collect Washes 2. Add 50ul of Elution Buffer to the beads, bind for 5’ shaking at RT. 
Bind beads to the magnets and collect Elution1 samples. Bind beads to the magnets and 
collect Elution2 samples.  
 
Binding to Lipid Strip assays  
Membrane lipid stripsTM were obtained from Echelon Bioscience (P-6002 and P-6003). 
Lipid strips were assayed, following the manufacturer’s instructions. Briefly, the 
membrane was blocked with 3% of fatty acid-free BSA in TBS-Tween 0.1% and gently 
agitate O/N at 4ºC. After discarding the blocking solution, the membrane was incubated 
with 10 µg/ml of protein at room temperature for 1 h. The protein solution was discarded, 
and the membrane washed for about 8 min with TBS-Tween 0.1% (repeated this step 4–
5 times). The membrane was then incubated with a 1:1,000 dilution of primary antibody  
in 3% of fatty acid-free BSA TBS-Tween 0.1%. Gently agitated for 1 h at RT. The 
antibody solution was discarded, and the membrane washed for about 8 min with TBS-
Tween 0.1% (repeated this step 4–5 times). The membrane was incubated with a 1:25,000 
dilution of secondary antibody in 3% of fatty acid-free BSA TBS-Tween 0.1%. Gently 
agitated for 1 h at RT. The secondary antibody solution was discarded, and the membrane 
washed for about 8 min with TBS-Tween 0.1% (repeated this step 4–5 times). The bound 
of protein to lipid was detected by Chemiluminescent or ECL. 
 
Lipid binding by liposome flotation assays 
Phospholipids and E. coli lipids were obtained from Avanti Polar Lipids, unless is stated. 
Lipids in stock solution in chloroform were prepared at 1 mM concentration (according 
to https://bio-protocol.org/e2169 and (Apellániz and Nieva, 2015)): 80% of:  E. coli 
(100500P) or PC (860355P) and 20% of: PC (860355P), PS (840037P), PA (830855P), 
PE (850705P) or PI (P2517-25MG). The lipid suspension was incubated at room 
temperature for 1 hour. Then, it was first sonicated during 4 cycles of 3 minutes each 
(Ultrasonic Cleaner; Branson 200) and then 5 freeze/thaw cycles in liquid nitrogen/warm 
water (26ºC) were performed to break the lipid cake. Finally the liposome mix was 
extruded through 400 nm polycarbonate membrane filter using a mini-extruder for large 




 Five µl of protein (≈1.5µM) were incubated with 45 µl of E. coli or PC liposomes 
containing either PA, PE, PC, PS or PI in TBS 1X during 1 hour at room temperature as 
reported. After the incubation, the mixture was subjected to liposome flotation. Briefly, 
the 50 μl of liposome/protein mixture was put into 800 μl of an ultracentrifuge tube 
(Beckman Coulter, ref: 343776) and mixed with 120 μl of TBS 1X containing 60% 
sucrose (Sigma). The mixture was subsequently overlaid by 200 μl of TBS 1X containing 
27% sucrose and then by 150 μl of TBS 1X containing 17% sucrose. After centrifugation 
at 84000 rpm for 3h at 4ºC, fractions were collected from top to bottom with a Hamilton 
syringe, and each fraction was analyzed by western blotting as reported (Apellániz and 
Nieva, 2015). 
 
Lipid extraction assay  
To monitor PS transfer extraction from liposomes we followed the protocol proposed by 
Kawano et. al.(Kawano et al., 2018; Krick et al., 2012). 200 µM liposomes: 80% of PC 
(860355P) and 20% of NBD-PS (810193P) or NBD-PE (810154P), were hydrated in TBS 
1X (50 mM Tris-Cl, pH 7.5, 150 mM NaCl). The lipid suspension was incubated at room 
temperature for 1 hours. Then, it was first sonicated during 4 cycles of 3 minutes each 
(Ultrasonic Cleaner; Branson 200) and then 5 freeze/thaw cycles in liquid nitrogen/warm 
water (26ºC) were performed to break the lipid cake. Finally the liposome mix was 
extruded through 400 nm polycarbonate membrane filter using a mini-extruder for large 
unilamellar vesicles (LUVs) formation. For lipid extraction, 10 µl of protein (≈3 µM) of 
protein were mixed with 90 µl of liposomes in 100µl TBS 1X and incubated at room 
temperature for 3 hours. After the incubation, the mixture was subjected to liposome 
flotation. The mixture of liposome/protein in TBS 1X was put into 5 ml of an 
ultracentrifuge tube (Beckman Coulter, ref: 344057) and mixed with 1400 μl of buffer A 
(20mM Tris-HCl, pH 7.4, and 150mM NaCl) and 1500 μl of buffer A containing 80% 
Nycodenz AG (Axis-Shield). The mixture was subsequently overlaid by 1500 μl of buffer 
A containing 30% Nycodenz AG and then 900 μl of buffer A without Nycodenz AG (see 
figure 4A). After centrifugation at 54000 rpm for 2h at 4ºC, 2 different fractions, top and 
bottom, were collected and analyzed for fluorescence with Spectra fluorimeter 
(SYNERGY H1M Fluorescence plate reader) at excitation/emission 460-590nm and 








In vitro phospholipid FRET assays 
To monitor the kinetics of FRET reaction, we assessed a modified protocol reported by 
Potting et. al. and Connerth et al. (Connerth et al., 2012; Potting et al., 2013). Briefly, 
Donor liposomes (12,5 µM): 90% E. coli (100500P), 2% Rhod PE (810158P), 8% NBD-
PE (810154P) or NBD-PS (810193P) or NBD-PA (810174P) or NBD-PC (810131P)  
were resuspended in BLTS (10% sucrose in buffer BLT= 5mM Tris/HCl ph 7.4, 150mM 
NaCl), and acceptor liposomes (50µM): 90% E. coli (100500P) and 10% of PC (860355P) 
or PS (840037P) or PA (830855P) or PE (850705P) were resuspended in BLT buffer 
without sucrose. The lipid suspension was incubated at room temperature for 1 hour. 
Then, it was first sonicated during 4 cycles of 3 minutes each (Ultrasonic Cleaner; 
Branson 200) and then 5 freeze/thaw cycles in liquid nitrogen/warm water (26ºC) were 
performed to break the lipid cake. Finally the liposome mix was extruded through 400 
nm polycarbonate membrane filter using a mini-extruder for large unilamellar vesicles 
(LUVs) formation. The donor and acceptor liposomes were mix with 200nM of purified 
recombinant protein and fluorescence of NBD was monitored during 3 hours in TECAN 
SAFIRE II-BASIC at constant temperature of 25C. 
 
To TOPFluor liposomes: 12,5 µM Donor liposomes contained: 90%  E. coli (100500P), 
2%   Doxyl PC (810604P), 8%   TopFluor PS (810283P), or TopFluor PE (810282P) were 
resuspended in BLTS and mixed with the same acceptor liposomes prepared for NBD 




Donor liposomes (12,5 µM): 90% E. coli (100500P), 2% Rhod PE (810158P), 8% NBD-
PC (810131P)  or NBD-PS (810193P)  resuspended in BLTS and acceptor liposomes 
(50µM): 90% E. coli (100500P) and 10% of PC (860355P) or PS (840037P) resuspended 
in BLT were incubated with 200nM of recombinant Mfn2 (1-613) protein in 300 μl buffer 
TA (20 mM Tris/HCl pH 7.4, 150 mM NaCl, 1 mM EDTA) at 25°C. After incubation the 
mixture was placed on ice, mixed with 100 μl buffer TA30 (30% sucrose in TA) and 
incubated for 10 min. The mix was placed on an ultracentrifuge tube and overlaid with 




buffer TA. Tubes were centrifuged at 217,000 xg for 2.5 h. Fractions fraction of 750 μl 
from the top middle and bottom were collected to be analyzed (Connerth et al., 2012). 
Liposomes were identified by confocal following bibliographic examples of liposome 
imaging (Gabor, 2011; Ruozi et al., 2011). Confocal images were obtained with a spectral 
confocal microscope multiphoton (Leica, Mannheim, Germany) and a Leica confocal 
system equipped with a 3-channel multiband Leica scanner TCS SP5. To obtain confocal 
images a small drop of the extraction flotation assay sample (usually 5 µl) was transferred 
to a coverslip (slide) and directly observed. Samples were scanned using a 63z Leitz 
objective (oil) to analyze the liposomes using LAS AF software from Leica. The NBD 
was excited with the 488 laser.   
 
Statistical Analysis  
Phospholipid content measured by lipidomics was analyzed separately using a linear 
model in which type of sample (control or L-KO) and experimental batch were included 
as covariates. Values were previously Box-Cox transformed in order to fit the 
assumptions of the model. Adjusted mean groups and fold-changes were extracted from 
the models and presented in their original scale. Statistical significance was assessed 
using the corresponding F-test.  
The rest of the data presented in this work was analyzed with Student’s t test or ANOVA 
followed by post-hoc t tests. Data are presented as mean ± SEM unless stated. 
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